pocketful logo
Vivo Bio Tech Ltd logo

Vivo Bio Tech Ltd

NSE: BSE: 511509

27.03

(-0.62%)

Wed, 04 Mar 2026, 00:30 pm

Vivo Bio Tech Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    58.47

  • Net Profit

    7.28

  • P/B

    0.83

  • Sector P/E

    32.40

  • P/E

    8.01

  • EV/EBITDA

    4.38

  • Debt/Equity (Industry)

    0.28

  • Interest Cover (Industry)

    4.55

  • ROCE (Industry)

    8.79

  • RONW (Industry)

    6.83

  • ROE

    5.68

  • ROCE

    8.99

  • Debt/Equity

    0.96

  • EPS (TTM)

    2.04

  • Dividend Yield

    0

  • Book Value

    43.02

  • Interest Cover

    1.55

Analysis

all

thumbs up icon

Pros

  • Vivo Bio Tech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vivo Bio Tech is profitable, therefore cash runway is not a concern.
  • Vivo Bio Tech is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (26.3%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 1x debt.
thumbs up icon

Cons

  • Unable to evaluate Vivo Bio Tech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vivo Bio Tech's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • The level of debt compared to net worth has increased over the past 5 years (65.7% vs 72.5% today).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.6x annual interest expense, ideally 3x coverage).
  • Vivo Bio Tech's level of debt (72.5%) compared to net worth is high (greater than 40%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters35.1635.1639.0640.8538.88
FII00000
DII00000
Public64.8464.8460.9459.1561.12
Government00000

Read More

Technical Analysis

RSI

29.34

MACD

-0.67

50 DMA

29.37

200 DMA

33.95

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic41.0734.5330.7827.9924.2421.4514.91
Fibonacci34.5332.0330.4927.9925.4923.9521.45
Camarilla28.8328.2327.6327.9926.4325.8325.23

Pivots Level: Classic

R3

+13.08

41.07

R2

+6.54

34.53

R1

+2.79

30.78

27.99
27.99
Pivot Point
LTP: 26

S1

-3.75

24.24

S2

-6.54

21.45

S3

-13.08

14.91

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    27.22

  • 20-EMA

    27.77

  • 30-EMA

    28.18

  • 50-EMA

    28.94

  • 100-EMA

    30.65

  • 200-EMA

    32.98

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
26 Aug 2025agm
09 Jan 2025egm
26 Aug 2024agm
31 Aug 2023agm
08 Sept 2022agm
28 Aug 2021agm

Read More

Peer Comparison

Vivo Bio Tech Ltd logo

Vivo Bio Tech Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Vivo Bio Tech Ltd About

Vivo Bio Tech off ers services in the areas of In vivo & In vitro toxicity studies, Pharmacological investigations, Pharmacokinetic & toxic kinetic studies, Genotoxicity screening, Analytical services etc.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1987

Headquarters

CEO

Employees

Contact

Website icon

Website

http://www.vivobio.com

Email icon

Email

investors@vivobio.com

Phone icon

Phone

Location icon

Location

Survey #349/A Pregnapur Vlge, , Gajel, Telangana, 502311

Read More

Vivo Bio Tech Ltd Company History

YearHistory
2007
  • Secured status of Research Establishment from the Ministry of Environment & Forests for its preclinical research facility
2008
  • Secured status of Research Establishment from The Department of Scientific & Industrial Research for its custom research facility
  • Vivo Bio Tech Ltd appointed Dr. Venugopal as Additional Director.
2009
  • Received SEZ gazette notification from Government of India for the companys land at Pregnapur for developing biotech specific Special Economic Zone
  • Vivo Bio Tech Ltd appointed Mr. K Jagan Mohan Rao as Additional Director.
2010
  • Commenced operations of 125,000 Sq.ft preclinical research facility Small Animals.
2011
  • Vivo Bio Tech preclinical research facility received Full Accreditation by AAALAC International.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
MAHESH RATHORESell1080003816 Sept 2025
MALLEMKONDA REALITIES PVTSell20639541.214 May 2025
MALLEMKONDA REALITIES PVTSell9430740.2713 May 2025
SUDHIRKUMARSell10310256.1822 Jan 2025
SUDHIRKUMARBuy10310255.2622 Jan 2025
EVERY WEAR IMPORT AND EXPORT PRIVATE LIMITEDSell23744841.6103 Jan 2025
VEAN SMART INFRA PRIVATE LIMITEDSell8142137.5106 Dec 2024
VEAN SMART INFRA PRIVATE LIMITEDSell7552838.6929 Nov 2024
MORE AGRISUPPLIES & SERVICES PRIVATE LIMITEDSell8281240.0626 Apr 2022
VEAN SMART INFRA PRIVATE LIMITEDSell10290036.7515 Feb 2022

Read More

Vivo Bio Tech Ltd News

Vivo Bio Tech Promoter Acquires 90,000 Shares

Kompella Lopa Mudra, promoter group member of Vivo Bio Tech Limited, acquired 90,000 equity shares through warrant conversion on January 06, 2026, maintaining 3.09% total shareholding.

09 Jan 2026

co actions results

Virinchi Allots 86L Warrants to Vivo Bio Tech

Virinchi Limited's committee approved allotment of 86 lakh convertible equity warrants to Vivo Bio Tech Limited at ₹28 per warrant, receiving ₹6.02 crores as 25% upfront payment.

08 Jan 2026

co actions results

Vivo Bio Tech Subscribes to ₹6.02 Cr Warrants

Vivo Bio Tech Limited has subscribed to 86 lakh convertible equity warrants of Virinchi Limited on preferential basis at ₹28 per warrant, paying ₹6.02 crores upfront.

08 Jan 2026

co actions results

Vivo Bio Tech allots 90,000 shares on warrant conversion

Vivo Bio Tech Limited allotted 90,000 equity shares at ₹45 each to promoter group member Kompella Lopa Mudra through warrant conversion, raising ₹30.38 lakh and increasing share capital to ₹22.19 crore.

06 Jan 2026

co actions results

Vivo BioTech Reports Mixed Financial Performance for Quarter Ended September 30, 2025

Vivo BioTech Limited approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, at a board meeting held on November 14, 2025. The biotechnology company also allotted 22,06,739 equity shares during the quarter through conversion of warrants issued on preferential basis, while operating as a single-segment business focused on biotechnology services.

14 Nov 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800